

INDEX

SR. NO.	TOPIC	PAGE NO.
	Contents	I-IV
	Abbreviations	V-VII
CHAPTER 1: Introduction		
1.1	Impurity profiling	2
1.1.1	Regulatory Guidelines on Impurities in an Active Pharmaceutical Ingredient	2
1.1.2	Classification of impurities	3
1.2	Introduction to tyrosine kinase inhibitors	7
1.2.1	Tyrosine kinase inhibitors	8
1.2.2	Imatinib mesylate	9
1.2.3	Dasatinib	11
1.3	TGR5 agonist	11
1.4	Combined objective of thesis	13
1.5	References	14
CHAPTER 2: Development and validation of derivatized chromatographic method to analyse genotoxic impurity hydrazine hydrate in Imatinib Mesylate API		
	List of figures	19
	List of tables	20
2.1	Introduction	21
2.1.1	Imatinib Mesylate	21
2.1.2	Hydrazine hydrate	22
2.1.3	Hypothesis	23
2.1.4	Objectives	24
2.2	Materials and equipment	24
2.2.1	Materials	24
2.2.2	Equipment	24
2.3	Preparation of solutions	25
2.3.1	Derivatization solution preparation	25
2.3.2	Acetic acid solution preparation	25
2.3.3	Standard solution preparation	25
2.3.4	Test solution preparation	25
2.4	Selection of derivatizing agent	25
2.5	Detection of impurity by LC-MS	27
2.6	HPLC instrumentations and working conditions	27
2.7	Analytical procedure	27

2.8	Method validation	28
2.9	Result and discussion	28
2.9.1	Optimization of derivatizing agent	28
2.9.2	Identification of impurity by LC-MS	31
2.9.3	Optimized HPLC parameters and Peak purity	32
2.9.4	System Suitability Criteria	35
2.9.5	Validation of the method	36
2.9.5.1	Selectivity (Specificity)	36
2.9.5.2	LOD and LOQ (Limit of Detection and Limit of Quantification)	36
2.9.5.3	Linearity and range	37
2.9.4.4	Precision	39
2.9.4.5	Accuracy	44
2.10	Conclusion	47
2.11	Reference	47

CHAPTER 3: Development and validation of residual solvent determination by head space gas chromatography in Imatinib Mesylate API

	List of figures	52
	List of tables	53
3.1	Introduction	54
3.1.1	Introduction to residual solvent	54
3.1.2	Head space gas-chromatography	55
3.2	Literature survey	57
3.3	Chemical, material, and reagents	57
3.4	Instrumentation	57
3.4.1	Gas chromatographic conditions	57
3.4.2	Selection of detector and carrier gas	58
3.4.3	Selection of column	58
3.4.4	Selection of sample solvent (Diluent)	58
3.4.5	Chromatographic conditions	59
3.4.6	Optimization of headspace parameters	59
3.5	Preparation of standard and sample solution	60
3.6	Method validation	61
3.6.1	Specificity	62
3.6.2	Linearity and range	62
3.6.3	Method sensitivity	66
3.6.4	Accuracy (recovery)	66
3.6.5	Precision	78
3.6.6	System suitability	83
3.6.7	Robustness	84
3.7	Result	85
3.8	Conclusion	86
3.9	References	87

CHAPTER 4: Characterization of related impurities present in Dasatinib

	List of figures	91
	List of tables	94
4.1	Introduction	97
4.2	Route of synthesis for dasatinib	98
4.3	Structure Elucidation and Characterization of Dasatinib Impurity-1	99
4.4	Structure Elucidation and Characterization of Dasatinib Impurity-2	106
4.5	Structure Elucidation and Characterization of 2-Amino-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide (Impurity 3)	114
4.6	Structure Elucidation and Characterization of 4-(2-(4-(6-((5-((2-chloro-6-methylphenyl)carbamoyl)thiazol-2-yl) amino)-2-methylpyrimidin-4-yl)piperazin-1-yl)ethoxy)-4-oxobutanoic acid(Impurity-4)	121
4.7	Structure Elucidation and Characterization of N-(2-chloro-6-methylphenyl)-2-[(6-chloro-2-methyl-4-pyrimidinyl)amino]-5-thiazole carboxamide (Impurity 5)	130
4.8	Structure Elucidation and Characterization of 2-(4-(6-((5-((2-chloro-6-methylphenyl)carbamoyl)thiazol-2-yl)amino)-2-methylpyrimidin-4-yl)piperazin-1-yl)ethyl acetate (Impurity 6)	138
4.9	Reference	147

CHAPTER 4a: Development and validation of chromatographic method for determination of impurities in solid dispersion of Dasatinib

	List of figures	150
	List of tables	152
4a.1	Introduction	153
4a.2	Materials and equipment	154
4a.2.1	Materials and reagents	154
4a.2.2	Equipments	154
4a.2.3	Preparation of solutions	154
4a.2.4	Generation of stress samples	155
4a.2.5	Detection of impurity by LC-MS	156
4a.2.6	HPLC instrumentation and working conditions	156
4a.2.7	Analytical procedure	157
4a.2.8	Method validation	157
4a.3	Result and discussion	157
4a.3.1	Identification of impurity by LC-MS	157
4a.3.2	Optimized HPLC parameters	161
4a.3.3	System suitability criteria	166

4a.3.4	Validation of the method	166
4a.3.4.1	Selectivity (Specificity)	166
4a.3.4.2	LOD and LOQ	175
4a.3.4.3	Linearity and range	177
4a.3.4.4	Precision	182
4a.3.4.5	Accuracy	191
4a.3.4.6	Robustness	198
4a.3.5	Application of method	198
4a.4	Conclusion	199
4a.5	References	200

CHAPTER 5: Impurity profiling of novel 2-thio imidazole derivative ZY12201 -an antidiabetic agent

	List of figures	205
	List of tables	206
5.1	Introduction	207
5.2	Synthesis and crystallization	208
5.3	Single crystal XRD	208
5.3.1	Structure description	209
5.4	Crystal structure determination of ZY12201	219
5.5	Materials and Equipments	220
5.5.1	Materials and Reagents	220
5.5.2	Equipments	220
5.5.3	Preparation of Solutions	221
5.6	Chromatographic method development conditions	221
5.7	Force degradation study	223
5.7.1	Outcomes of forced degradation studies	223
5.7.2	Objective for forced degradation	523
5.8	Various degradation conditions	224
5.8.1	Control sample	226
5.8.2	Hydrolysis	227
5.8.3	Oxidation	228
5.8.4	Photolytic condition	229
5.8.5	Thermal conditions	230
5.8.6	Peak Purity	231
5.9	Summary of Force Degradation Study	234
5.10	Identification of impurity by LC-MS	235
5.11	Conclusion	237
5.12	Reference	238

CHAPTER 6: Scope and conclusion
